Blood test–guided monitoring for metastatic breast cancer treatment
Part of Cancer clinical trials.
This study checks whether specific blood “tumor marker” levels can help monitor how hormone receptor–positive, HER2-negative metastatic breast cancer responds to first-line therapy. It uses regular blood tests (and sometimes scans) to see if this marker-based monitoring is useful and reliable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hormone receptor–positive (ER+ and/or PR+), HER2-negative metastatic (stage M1) breast cancer
- You are starting first-line treatment for metastatic disease (hormone therapy, with or without other whole-body treatments)
- After your metastatic diagnosis, you had blood tumor marker tests (CEA and at least one of CA 15-3 or CA 27.29) within about 2 weeks of starting treatment
- At least one marker was clearly higher than normal (about 1.5× the lab’s upper limit) and you can keep using the same two markers for monitoring
- You had imaging (scans) before starting treatment or within 30 days, and you can get ongoing monitoring from the same facility
- You don’t have certain conditions that can falsely raise marker blood results (like cirrhosis, untreated B12 deficiency, thalassemia, or sickle cell)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a blood test (DiviTum TKa) to see how well it measures treatment response in people with hormone receptor-positive (HR+) breast cancer that has spread. The test may help doctors know if a treatment is working.
This trial studies using a blood test to monitor how treatment is working in people with metastatic breast cancer. It may help your care team track your cancer over time with a simpler test.
This Phase 2 study uses a blood test that looks for “circulating tumor DNA” to help decide if standard chemotherapy should be changed. It aims to see whether this approach improves how well treatment works for certain metastatic (stage IV) breast cancers.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This study looks at a blood test that measures certain markers on cancer cells (CTCs) and genetic material in the blood (cfDNA/RNA) in women with metastatic breast cancer. It aims to better understand the cancer and guide treatment decisions.
This study examines tiny particles in your blood from breast cancer cells to better predict which treatments will work best for you. Researchers will collect blood samples and a small tissue sample to understand your cancer's characteristics and help doctors choose more effective therapy.
Hear when a new Anatomic Stage IV Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.